Oncology – Breast
The incidence of breast cancer recurrence 10-32 years after primary diagnosis.
22 Mar, 2022 | 08:12h | UTC
M-A: Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer.
16 Mar, 2022 | 08:30h | UTC
RCT: Overall survival with Ribociclib plus Letrozole in advanced breast cancer.
11 Mar, 2022 | 09:47h | UTCOverall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Adding Ribociclib to Letrozole Prolongs Survival in Advanced Breast Cancer – HealthDay
Mapping systematic reviews of breast cancer survivorship interventions.
10 Mar, 2022 | 10:16h | UTC
Commentary on Twitter
? Despite vast volume, review-level #BreastCancer #survivorship research is unevenly distributed and siloed. Strategic planning of future research, in consultation with survivors, is needed. ➡️ https://t.co/pxMp5XK8B8 #JCO #BCSM @EmmaBKemp1 #survonc pic.twitter.com/TRjOEJQbrw
— Journal of Clinical Oncology (@JCO_ASCO) March 5, 2022
RCT: Efficacy of HD201 vs. referent Trastuzumab in patients With ERBB2-positive breast cancer treated in the neoadjuvant setting.
9 Mar, 2022 | 08:22h | UTC
Commentary on Twitter
Trastuzumab dramatically improves outcome of HER2-positive breast cancer, though its high price limits access. HD201 is a biosimilar tested vs trastuzumab in HER2-positive early breast cancer, showing equivalence in pathologic complete response rates https://t.co/CycdYdXpMC #BCSM
— JAMA Oncology (@JAMAOnc) March 4, 2022
New research finds breast cancer overdiagnosis not as common as previously thought.
7 Mar, 2022 | 00:36h | UTCEstimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort – Annals of Internal Medicine (link to abstract – $ for full-text)
Breast cancer overdiagnosis may not happen as frequently as previously thought – ACP Internist
Cancer risks other than female breast and ovarian cancers associated with BRCA1 and BRCA2 pathogenic variants.
3 Mar, 2022 | 08:14h | UTCCancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants – Journal of Clinical Oncology
Commentary: Faulty BRCA genes linked to prostate and pancreatic cancers – University of Cambridge
RCT: Referral for early, supported exercise after breast cancer surgery improves shoulder function and health-related quality of life.
1 Mar, 2022 | 08:50h | UTCFull Report: Exercise to prevent shoulder problems after breast cancer surgery: the PROSPER RCT – Health Technology Assessment
Screening Algorithms in Dense Breasts: AJR Expert Panel Narrative Review.
24 Feb, 2022 | 10:11h | UTC
M-A: Immune checkpoint inhibitors combined with chemotherapy compared with chemotherapy alone for triple-negative breast cancer.
17 Feb, 2022 | 08:13h | UTC
Aromatase inhibitors vs. tamoxifen in premenopausal women with estrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomized trials
13 Feb, 2022 | 21:32h | UTCCommentaries:
Aromatase Inhibitors May Benefit Premenopausal Women With Breast Cancer – HealthDay
RCT: Event-free survival with pembrolizumab in early triple-negative breast cancer.
11 Feb, 2022 | 08:35h | UTCEvent-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary (before publication): KEYNOTE-522: Neoadjuvant Pembrolizumab Improves Event-Free Survival in Triple-Negative Breast Cancer – The ASCO Post
Abemaciclib with endocrine therapy in the treatment of high-risk early breast cancer: ASCO optimal adjuvant chemotherapy and targeted therapy guideline rapid recommendation update.
10 Feb, 2022 | 08:33h | UTC
RCT: Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer–Related Lymphedema.
4 Feb, 2022 | 08:35h | UTC
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicenter pooled analysis of 5161 patients.
2 Feb, 2022 | 08:22h | UTC
Observational Study: Same-day mastectomy and axillary lymph node dissection seems safe for most patients with breast cancer.
1 Feb, 2022 | 08:38h | UTC
Outcome of patients with an ultralow-risk 70-gene signature in the MINDACT trial.
24 Jan, 2022 | 08:08h | UTCOutcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)
Related:
Commentary on Twitter:
In MINDACT, 15% of the pts (n=1000) had an ultra-low 70-gene signature. Although some had tumors >2 cm (20%) & were LN+ (20%), prognosis was outstanding
8-year DMFI 97%
8-year BCSS 99.6%Most of these patients received adj treatment. Did they need it?https://t.co/V9SH2StuQE
— Paolo Tarantino (@PTarantinoMD) January 22, 2022
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update.
20 Jan, 2022 | 08:57h | UTC
Commentary on Twitter
Out on @JCO_ASCO the new ASCO/OH guidelines for adjuvant bisphosphonates in BC
Important to weight risks and benefits based on the risk profile of the disease, financial toxicity, drug availability, patient preferences, comorbidities & life expectancy. https://t.co/6noyYplALB
— Paolo Tarantino (@PTarantinoMD) January 18, 2022
M-A: Beta-blockers and renin–angiotensin system inhibitors may provide a modest benefit for the preservation of left ventricular function in patients with breast cancer treated with anthracyclines or trastuzumab.
19 Jan, 2022 | 08:34h | UTCA systematic review and meta-analysis of beta-blockers and renin–angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer – European Journal of Cardiology (link to abstract – $ for full-text)
Commentary: BBs, ACEI/ARBs to Prevent LV Dysfunction Due to Breast Cancer Drugs – American College of Cardiology
Adjuvant Capecitabine for early breast cancer: 15-year overall survival results from a randomized trial.
18 Jan, 2022 | 09:11h | UTC
Final overall survival analysis of the HER2CLIMB RCT: Tucatinib vs. placebo added to Trastuzumab and Capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases.
13 Jan, 2022 | 08:12h | UTCTucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis – Annals of Oncology (link to abstract – $ for full-text)
Original Study: Randomized Trial: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
RCT: In premenopausal women with breast cancer, gonadotropin-releasing hormone analogs may preserve ovarian function against chemotherapy-induced gonadotoxic effects.
11 Jan, 2022 | 02:26h | UTCEffects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Randomized clinical trial finds administration of gonadotropin-releasing hormone analogs (GnRHa) with chemotherapy in premenopausal pts with #BreastCancer reduces risk of premature ovarian insufficiency (#POI) and promotes recovery of ovarian function. https://t.co/gymbKT9GWZ pic.twitter.com/OUOlIwPSsq
— JAMA Oncology (@JAMAOnc) December 30, 2021
RCT: In patients presenting with metastatic breast cancer, early locoregional therapy for the primary site did not improve survival or quality of life.
11 Jan, 2022 | 02:29h | UTCEarly Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Systematic Review: Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer.
9 Dec, 2021 | 10:08h | UTC
Commentary on Twitter (thread – click for more)
Our comprehensive #systematicreview for the #ECIBC on intervals (every 1, 2, 3 years) of #breastcancer #screening is available.
We included RCT, observational, and mathematical modeling studies to assess benefits and harms and applied the #GRADE approachhttps://t.co/IfplsWfKuA pic.twitter.com/7niEbnaWKR— Carlos Canelo-Aybar (@ccaneloa) November 27, 2021
RCT: 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.
2 Dec, 2021 | 09:49h | UTC21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Among postmenopausal women with HR–positive, HER2-negative breast cancer, 1-3 positive lymph nodes, and a 21-gene recurrence score of 25 or lower, 5-year invasive disease–free survival was similar whether they received endocrine or chemoendocrine therapy. https://t.co/aZLXBvSHHl pic.twitter.com/EBVnMkGHx4
— NEJM (@NEJM) December 2, 2021